Assembling the evidence…
Drug development is both increasing in cost whilst decreasing in productivity. There is a general acceptance that the current paradigm of R&D needs to change. One alternative approach is drug repositioning. With target-based approaches utilised heavily in the field of drug discovery, it becomes increasingly necessary to have a systematic method to rank gene-disease associations. Although methods already exist to collect, integrate and score these associations, they are often not a reliable reflection of expert knowledge. Furthermore, the amount of data available in all areas covered by bioinformatics is increasing dramatically year on year. It thus makes sense to move away from more generalised hypothesis driven approaches to research to one that allows data to generate their own hypothesis. We introduce an integrated, data driven approach to drug repositioning. We first apply a Bayesian statistics approach to rank 309,885 gene-disease associations using existing knowledge. Ranked associations are then integrated with other biological data to produce a semantically-rich drug discovery network. Using this network, we show how our approach identifies diseases of the central nervous system (CNS) to be an area of interest. CNS disorders are identified due to the low numbers of such disorders that currently have marketed treatments, in comparison to other therapeutic areas. We then systematically mine our network for semantic subgraphs that allow us to infer drug-disease relations that are not captured in the network. We identify and rank 275,934 drug-disease has_indication associations after filtering those that are more likely to be side effects, whilst commenting on the top ranked associations in more detail. The dataset has been created in Neo4j and is available for download at https://bitbucket.org/ncl-intbio/genediseaserepositioning along with a Java implementation of the searching algorithm.
Strengths
The paper integrates ranked gene-disease evidence with drug, target, protein, disease, indication, and side-effect data in a Neo4j network. It reports 55,973 nodes, 529,738 edges, and 275,934 inferred unique drug-disease associations after filtering.
↳ Materials and Methods, Integrated Dataset; Results, Mining
The mining workflow reports a clear sequence from 539,162 raw mappings through side-effect, directionality, and ADME filtering to 451,269 retained mappings. These counts make the computational pipeline unusually traceable for a hypothesis-generation study.
↳ Results, Mining
The Discussion explains how missing directionality could make the top CNS inference, Nitrendipine for hypokalemic periodic paralysis, harmful rather than therapeutic. This example grounds the limitation in a concrete failure mode rather than a generic caveat.
↳ Discussion, paragraph on directionality and Nitrendipine
Limitations
The D parameter and MeSH similarity thresholds are selected because they optimise AUC or trade-offs on the available data. This makes the reported performance less convincing as evidence of prospective predictive ability.
↳ Results, Ranking Gene-Disease Associations; Results, Mining; Discussion, paragraph on Sim values
Known has_indication associations used for validation are drawn from the same integrated network environment that supports prediction. The 72.65% recovery rate and AUC of 0.73 therefore mainly support retrospective recovery, not out-of-sample drug-repositioning performance.
↳ Materials and Methods, Integrated Dataset; Results, Mining; Fig 5
The article identifies a real drug-repositioning need and provides downloadable outputs, but it does not describe how industry or academic teams should use the ranked associations to select candidates for validation. Highlighted examples such as Pazopanib and Lisinopril remain literature-supported hypotheses rather than tested repositioning leads.
↳ Results, Pazopanib and Lisinopril sections; Discussion
The score is driven by a competent and transparent computational workflow that integrates heterogeneous gene-disease and drug-target evidence at useful scale. Contribution is moderated because the central statistical scoring and subgraph search are adapted from existing methods, making the novelty primarily integrative. Methodological Rigour is held in the low-to-mid 3 range because performance-related parameters are chosen on observed trade-offs and validation is retrospective rather than clearly independent. Impact potential is real in drug-repositioning triage, but the article’s own Discussion shows that directionality, target reachability, and experimental validation remain major steps before practical use.
Moderate3.2/5.0
The paper’s contribution lies in assembling a ranked gene-disease evidence base, integrating it into a semantic drug-discovery graph, and producing a large candidate indication list. Its novelty is moderated because the Bayesian ranking approach is adapted from Lee et al. and the mining algorithm is based on prior work.
"We identify and rank 275,934 drug-disease has_indication associations"
The design is coherent for computational hypothesis generation, with explicit equations, source integration, graph construction, filtering counts, and validation against known indications. Methodological Rigour is limited by retrospective parameter tuning, partly internal validation, incomplete directionality data, and pragmatic unvalidated scoring choices such as assigned DrugBank activity values.
"a D value of 5.0 was used... as it was deemed to optimise the area under the curve"
The paper has a clear progression from motivation to workflow, equations, graph mining, therapeutic-area results, and case studies. It generally marks predictions as hypotheses and explicitly discusses limitations, though terms such as data-driven and treatment proposals sometimes run ahead of the evidence.
"As such, we propose lisinopril as a potential treatment"
The paper situates the work among gene-disease databases, disease vocabularies, and prior computational repositioning approaches including Chiang, Gottlieb, Huang, and Daminelli. Positioning is less complete on comparative performance because the paper does not benchmark its AUC and recovery rates head-to-head against those alternatives.
"Existing methodologies are based on: chemical structure similarity... phenotype similarity... and genetic variation"
Watch-outs4 of 4 checks
The workflow and reported counts are broadly internally coherent, but several performance-related choices are tuned on the available data and validation is not clearly out-of-sample. A redacted citation placeholder for the key subgraph algorithm also limits documentation of one methodological dependency without contradicting the numerical results.
The study uses public computational resources and presents no ethics or fabrication concerns, but reproducibility claims depend on repository contents and supplementary mapping files that were not verified in the supplied material. Claimed data and Java code availability are specific enough to record, but not independently confirmed here.
Flags: 2 declared / 5 total
All 58 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.
No retraction notice found in Retraction Watch.
Sources: Retraction Watch ✓PubPeer (coming soon)
Medium3.0/5.0
The paper addresses drug development cost, productivity, and systematic repositioning, which are recognisable needs for pharmaceutical and academic discovery groups. Relevance is moderated because the article does not specify adopting organisations, decision workflows, or implementation steps beyond making a database and algorithm available.
"many pharmaceutical companies now have groups focused purely on repositioning"
The outputs are computationally generated hypotheses validated retrospectively against known indications, not experimentally or clinically tested candidates. The article itself frames further filtering and validation as necessary before the predictions could be used as therapeutic leads.
"the next step would require a more robust filtering of the results"
The method is designed across therapeutic areas and reports inferred indications throughout the MeSH hierarchy, with detailed attention to C04 and C10. Generalizability is constrained by variable data availability, disease mapping quality, side-effect filtering, and incomplete directionality or target-reachability information.
"systems approaches are limited by the data available"
The work connects to an active trajectory in network-based computational repositioning and contributes a dataset that could support future target-identification and validation work. Its trajectory remains moderate because the paper mainly provides infrastructure and hypotheses rather than demonstrated uptake or prospective validation.
"this in silico approach will complement target identification and validation"
Nabu’s assessment, alongside the field’s view.
Evaluation Metadata
AI-powered, human-governed. Something look off? Contact us to request a review.